Article Text

Download PDFPDF
Hormone therapy for younger women may not increase CHD risk during 5–7 years follow-up, but stroke risk was increased independent of age

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Clinical impact ratings GP/FP/Primary care ★★★★★★☆ Gynaecology ★★★★★★★ Cardiology ★★★★★☆☆ IM/Ambulatory care ★★★★★☆☆


Embedded ImageDesign:

2 randomised placebo-controlled trials (Women’s Health Initiative [WHI] trials).

Embedded ImageAllocation:


Embedded ImageBlinding:

blinded {clinicians, participants, data collectors, outcome assessors, and monitoring committee}*.

Embedded ImageFollow-up period:

mean 5.6 and 7.1§ years.

Embedded ImageSetting:

40 US clinical centres.

Embedded ImageParticipants:

27 347 predominantly healthy postmenopausal women 50–79 years of age (mean age 63* and 64|| y).

Embedded ImageIntervention

conjugated equine oestrogen (CEO), 0.625 mg/day, plus medroxyprogesterone acetate, 2.5 mg/day (n = 8506), or placebo (n = 8102) in women with an intact uterus; CEO, 0.625 mg/day (n = 5310), or placebo (n = 5429) in women with a hysterectomy.

Embedded ImageOutcomes:

coronary heart disease (CHD) (myocardial infarction or CHD death), stroke, total mortality, and a global index.

Embedded ImageParticipant follow-up:

94%|| (intention-to-treat analysis).


Overall, the HT and placebo groups did not differ for CHD, total mortality, and the global index; the risk of stroke was higher in the HT group …

View Full Text


Linked Articles

  • Glossary
    BMJ Publishing Group Ltd